
Results
18
Companies which are more than 50% undervalued based on analyst price target.
18 companies
Nanobiotix
Market Cap: €1.7b
Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
NANO
€33.40
7D
-7.7%
1Y
681.3%
Inventiva
Market Cap: €925.0m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.92
7D
2.5%
1Y
42.4%
DBV Technologies
Market Cap: €732.1m
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV
€2.47
7D
-12.7%
1Y
58.8%
Valneva
Market Cap: €404.3m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.13
7D
-3.4%
1Y
-17.9%
Transgene
Market Cap: €200.5m
A biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
TNG
€0.73
7D
-1.6%
1Y
-8.0%
Cellectis
Market Cap: €176.3m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.43
7D
-4.4%
1Y
58.7%
Innate Pharma
Market Cap: €145.6m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.55
7D
-2.1%
1Y
-5.7%
Sensorion
Market Cap: €134.1m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.26
7D
0.2%
1Y
-16.0%
OSE Immunotherapeutics
Market Cap: €75.8m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.22
7D
-2.5%
1Y
-36.8%
Adocia
Market Cap: €73.4m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€3.75
7D
-2.7%
1Y
-12.0%
ABIONYX Pharma
Market Cap: €65.8m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€1.86
7D
-0.4%
1Y
50.6%
THX Pharma Société Anonyme
Market Cap: €53.1m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€3.85
7D
-2.0%
1Y
253.2%
MaaT Pharma
Market Cap: €52.1m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.77
7D
-2.6%
1Y
-36.0%
AB Science
Market Cap: €45.6m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.57
7D
-10.9%
1Y
-52.5%
Nicox
Market Cap: €33.0m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.38
7D
-3.5%
1Y
22.5%
Advicenne
Market Cap: €23.6m
A specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally.
ALDVI
€1.62
7D
-10.0%
1Y
37.1%
GenSight Biologics
Market Cap: €19.3m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.082
7D
1.4%
1Y
-35.3%
Valbiotis
Market Cap: €18.1m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.77
7D
-3.0%
1Y
-8.0%